Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.

Damont A, Goutal S, Auvity S, Valette H, Kuhnast B, Saba W, Tournier N.

Eur J Pharm Sci. 2016 Aug 25;91:98-104. doi: 10.1016/j.ejps.2016.06.005. Epub 2016 Jun 7.

PMID:
27283486
2.

Differential influence of propofol and isoflurane anesthesia in a non-human primate on the brain kinetics and binding of [(18)F]DPA-714, a positron emission tomography imaging marker of glial activation.

Saba W, Goutal S, Kuhnast B, Dollé F, Auvity S, Fontyn Y, Cayla J, Peyronneau MA, Valette H, Tournier N.

Eur J Neurosci. 2015 Jul;42(1):1738-45. doi: 10.1111/ejn.12946. Epub 2015 Jun 22.

PMID:
25962575
3.

Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.

Tournier N, Saba W, Goutal S, Gervais P, Valette H, Scherrmann JM, Bottlaender M, Cisternino S.

AAPS J. 2015 May;17(3):652-9. doi: 10.1208/s12248-015-9739-3. Epub 2015 Feb 26.

4.

Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.

Tournier N, Saba W, Cisternino S, Peyronneau MA, Damont A, Goutal S, Dubois A, Dollé F, Scherrmann JM, Valette H, Kuhnast B, Bottlaender M.

AAPS J. 2013 Oct;15(4):1082-90. doi: 10.1208/s12248-013-9514-2. Epub 2013 Aug 2.

5.

[(18)F]Fallypride: metabolism studies and quantification of the radiotracer and its radiometabolites in plasma using a simple and rapid solid-phase extraction method.

Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Bottlaender M, Valette H.

Nucl Med Biol. 2013 Oct;40(7):887-95. doi: 10.1016/j.nucmedbio.2013.06.003. Epub 2013 Jul 25.

PMID:
23891202
6.

Metabolism and quantification of [(18)F]DPA-714, a new TSPO positron emission tomography radioligand.

Peyronneau MA, Saba W, Goutal S, Damont A, Dollé F, Kassiou M, Bottlaender M, Valette H.

Drug Metab Dispos. 2013 Jan;41(1):122-31. doi: 10.1124/dmd.112.046342. Epub 2012 Oct 12.

7.

Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.

Tournier N, Cisternino S, Peyronneau MA, Goutal S, Dolle F, Scherrmann JM, Bottlaender M, Saba W, Valette H.

Pharm Res. 2012 Sep;29(9):2468-76. doi: 10.1007/s11095-012-0776-7. Epub 2012 May 30.

PMID:
22644589
8.

Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling: part II: Metabolism studies.

Peyronneau MA, Saba W, Dollé F, Goutal S, Coulon C, Bottlaender M, Valette H.

Nucl Med Biol. 2012 Apr;39(3):347-59. doi: 10.1016/j.nucmedbio.2011.09.006. Epub 2011 Dec 11.

PMID:
22154687
9.

Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies.

Saba W, Peyronneau MA, Dollé F, Goutal S, Bottlaender M, Valette H.

Nucl Med Biol. 2012 Feb;39(2):227-33. doi: 10.1016/j.nucmedbio.2011.08.003. Epub 2011 Oct 26.

PMID:
22033025
10.

Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.

Tournier N, Valette H, Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Scherrmann JM, Cisternino S, Bottlaender M.

J Nucl Med. 2011 Mar;52(3):415-23. doi: 10.2967/jnumed.110.079608. Epub 2011 Feb 14.

11.

[18F]ZW-104, a new radioligand for imaging alpha2-alpha3-alpha4/beta2 central nicotinic acetylcholine receptors: Evaluation in mutant mice.

Saba W, Valette H, Granon S, Xiao Y, Kellar KJ, Dollé F, Bottlaender M.

Synapse. 2010 Jul;64(7):570-2. doi: 10.1002/syn.20776. No abstract available.

PMID:
20222155
12.

In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approach.

Bottlaender M, Valette H, Delforge J, Saba W, Guenther I, Curet O, George P, Dollé F, Grégoire MC.

J Cereb Blood Flow Metab. 2010 Apr;30(4):792-800. doi: 10.1038/jcbfm.2009.242. Epub 2009 Nov 18.

13.

[(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate.

Saba W, Valette H, Peyronneau MA, Bramoullé Y, Coulon C, Curet O, George P, Dollé F, Bottlaender M.

Synapse. 2010 Jan;64(1):61-9. doi: 10.1002/syn.20703.

PMID:
19728365
14.

18F-ZW-104: a new radioligand for imaging neuronal nicotinic acetylcholine receptors--in vitro binding properties and PET studies in baboons.

Valette H, Xiao Y, Peyronneau MA, Damont A, Kozikowski AP, Wei ZL, Kassiou M, Kellar KJ, Dollé F, Bottlaender M.

J Nucl Med. 2009 Aug;50(8):1349-55. doi: 10.2967/jnumed.108.061374.

15.

Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.

Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Grégoire MC, Coulon C, Valette H, Dollé F, Ribeiro MJ, Hantraye P, Remy P.

J Cereb Blood Flow Metab. 2009 Sep;29(9):1601-8. doi: 10.1038/jcbfm.2009.74. Epub 2009 Jun 3.

PMID:
19491921
16.

Beta-blocking agent for treatment of infantile hemangioma.

Bigorre M, Van Kien AK, Valette H.

Plast Reconstr Surg. 2009 Jun;123(6):195e-6e. doi: 10.1097/PRS.0b013e3181a3f435. No abstract available.

PMID:
19483538
17.

[18F]FPhEP and [18F]F2PhEP, two new epibatidine-based radioligands: evaluation for imaging nicotinic acetylcholine receptors in baboon brain.

Valette H, Dollé F, Saba W, Roger G, Hinnen F, Coulon C, Ottaviani M, Syrota A, Bottlaender M.

Synapse. 2007 Sep;61(9):764-70.

PMID:
17568410
18.

Quantification of cerebral nicotinic acetylcholine receptors by PET using 2-[18F]fluoro-A-85380 and the multiinjection approach.

Gallezot JD, Bottlaender MA, Delforge J, Valette H, Saba W, Dollé F, Coulon CM, Ottaviani MP, Hinnen F, Syrota A, Grégoire MC.

J Cereb Blood Flow Metab. 2008 Jan;28(1):172-89. Epub 2007 May 16.

PMID:
17519978
19.

[11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.

Saba W, Valette H, Schöllhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M.

Synapse. 2007 Jan;61(1):17-23.

PMID:
17068778
20.

Synthesis and radiolabeling of N-[4-[4-(2-[11C]methoxyphenyl)piperazin-1-yl]butyl]benzo[b]thiophene-2-carboxamide -- a potential radiotracer for D3 receptor imaging with PET.

Kuhnast B, Valette H, Besret L, Demphel S, Coulon C, Ottaviani M, Guillermier M, Bottlaender M, Dollé F.

Nucl Med Biol. 2006 Aug;33(6):785-95. Epub 2006 Jul 18.

PMID:
16934697
21.

Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study.

Picard F, Bruel D, Servent D, Saba W, Fruchart-Gaillard C, Schöllhorn-Peyronneau MA, Roumenov D, Brodtkorb E, Zuberi S, Gambardella A, Steinborn B, Hufnagel A, Valette H, Bottlaender M.

Brain. 2006 Aug;129(Pt 8):2047-60. Epub 2006 Jun 30.

PMID:
16815873
22.

Synthesis and radiosynthesis of [(18)F]FPhEP, a novel alpha(4)beta(2)-selective, epibatidine-based antagonist for PET imaging of nicotinic acetylcholine receptors.

Roger G, Saba W, Valette H, Hinnen F, Coulon C, Ottaviani M, Bottlaender M, Dollé F.

Bioorg Med Chem. 2006 Jun 1;14(11):3848-58. Epub 2006 Feb 7.

PMID:
16455259
23.

Improved synthesis of the peripheral benzodiazepine receptor ligand [11C]DPA-713 using [11C]methyl triflate.

Thominiaux C, Dollé F, James ML, Bramoullé Y, Boutin H, Besret L, Grégoire MC, Valette H, Bottlaender M, Tavitian B, Hantraye P, Selleri S, Kassiou M.

Appl Radiat Isot. 2006 May;64(5):570-3. Epub 2006 Jan 20.

PMID:
16427784
24.

Radiosynthesis of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor antagonist.

Thominiaux C, de Bruin B, Bramoullé Y, Hinnen F, Demphel S, Valette H, Bottlaender M, Besret L, Kassiou M, Dollé F.

Appl Radiat Isot. 2006 Mar;64(3):348-54. Epub 2005 Nov 22.

PMID:
16307887
25.

Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET.

Dollé F, Emond P, Mavel S, Demphel S, Hinnen F, Mincheva Z, Saba W, Valette H, Chalon S, Halldin C, Helfenbein J, Legaillard J, Madelmont JC, Deloye JB, Bottlaender M, Guilloteau D.

Bioorg Med Chem. 2006 Feb 15;14(4):1115-25. Epub 2005 Oct 10.

PMID:
16219467
26.

Acute inhibition of cardiac monoamine oxidase A after tobacco smoke inhalation: validation study of [11C]befloxatone in rats followed by a positron emission tomography application in baboons.

Valette H, Bottlaender M, Dollé F, Coulon C, Ottaviani M, Syrota A.

J Pharmacol Exp Ther. 2005 Jul;314(1):431-6. Epub 2005 Apr 15.

27.

Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys.

Valette H, Bottlaender M, Dollé F, Coulon C, Ottaviani M, Syrota A.

Synapse. 2005 Jun 15;56(4):217-21.

PMID:
15803498
28.

In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET.

Gallezot JD, Bottlaender M, Grégoire MC, Roumenov D, Deverre JR, Coulon C, Ottaviani M, Dollé F, Syrota A, Valette H.

J Nucl Med. 2005 Feb;46(2):240-7.

29.

Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors.

Roger G, Dollé F, De Bruin B, Liu X, Besret L, Bramoullé Y, Coulon C, Ottaviani M, Bottlaender M, Valette H, Kassiou M.

Bioorg Med Chem. 2004 Jun 15;12(12):3229-37.

PMID:
15158791
30.

Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[(11)C]one, as a potent NR(1A)/2B subtype selective NMDA PET radiotracer.

Roger G, Lagnel B, Besret L, Bramoullé Y, Coulon C, Ottaviani M, Kassiou M, Bottlaender M, Valette H, Dollé F.

Bioorg Med Chem. 2003 Dec 1;11(24):5401-8.

PMID:
14642584
31.

Synthesis of a [2-pyridinyl-18F]-labelled fluoro derivative of (-)-cytisine as a candidate radioligand for brain nicotinic alpha4beta2 receptor imaging with PET.

Roger G, Lagnel B, Rouden J, Besret L, Valette H, Demphel S, Gopisetti J, Coulon C, Ottaviani M, Wrenn LA, Letchworth SR, Bohme GA, Benavides J, Lasne MC, Bottlaender M, Dollé F.

Bioorg Med Chem. 2003 Dec 1;11(24):5333-43.

PMID:
14642577
32.

Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.

Dolle F, Valette H, Bramoulle Y, Guenther I, Fuseau C, Coulon C, Lartizien C, Jegham S, George P, Curet O, Pinquier JL, Bottlaender M.

Bioorg Med Chem Lett. 2003 May 19;13(10):1771-5.

PMID:
12729662
33.

Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers.

Bottlaender M, Valette H, Roumenov D, Dollé F, Coulon C, Ottaviani M, Hinnen F, Ricard M.

J Nucl Med. 2003 Apr;44(4):596-601.

34.

Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone.

Bottlaender M, Dolle F, Guenther I, Roumenov D, Fuseau C, Bramoulle Y, Curet O, Jegham J, Pinquier JL, George P, Valette H.

J Pharmacol Exp Ther. 2003 May;305(2):467-73. Epub 2003 Feb 11.

35.

Long-lasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys.

Valette H, Bottlaender M, Dollé F, Coulon C, Ottaviani M, Syrota A.

J Neurochem. 2003 Jan;84(1):105-11.

36.

Fluoro-A-85380 demonstrated no mutagenic properties in in vivo rat micronucleus and Ames tests.

Valette H, Dollé F, Bottlaender M, Hinnen F, Marzin D.

Nucl Med Biol. 2002 Nov;29(8):849-53.

PMID:
12453596
37.

In vivo quantification of myocardial dihydropyridine binding sites: a PET study in dogs.

Valette H, Dollé F, Guenther I, Fuseau C, Coulon C, Hinnen F, Péglion JL, Crouzel C.

J Nucl Med. 2002 Sep;43(9):1227-33.

38.

Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin transporter imaging with PET.

Karramkam M, Dollé F, Valette H, Besret L, Bramoullé Y, Hinnen F, Vaufrey F, Franklin C, Bourg S, Coulon C, Ottaviani M, Delaforge M, Loc'h C, Bottlaender M, Crouzel C.

Bioorg Med Chem. 2002 Aug;10(8):2611-23.

PMID:
12057650
39.

Anesthesia affects the disposition of [18F]fluoro-A-85380: a PET study in monkeys.

Valette H, Bottlaender M, Coulon C, Ottaviani M, Syrota A.

Synapse. 2002 Apr;44(1):58-9. No abstract available.

PMID:
11842447
40.

Myocardial kinetics of the (11)C-labeled enantiomers of the Ca(2+) channel inhibitor S11568: an in vivo study.

Valette H, Dollé F, Guenther I, Hinnen F, Fuseau C, Coulon C, Péglion JL, Crouzel C.

J Nucl Med. 2001 Jun;42(6):932-7.

41.

Synthesis of high-specific-radioactivity 4- and 6-[18F]fluorometaraminol-PET tracers for the adrenergic nervous system of the heart.

Langer O, Dollé F, Valette H, Halldin C, Vaufrey F, Fuseau C, Coulon C, Ottaviani M, Någren K, Bottlaender M, Maziére B, Crouzel C.

Bioorg Med Chem. 2001 Mar;9(3):677-94.

PMID:
11310603
42.

High specific radioactivity (1R,2S)-4-[(18)F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart.

Langer O, Valette H, Dollé F, Halldin C, Loc'h C, Fuseau C, Coulon C, Ottaviani M, Bottlaender M, Mazière B, Crouzel C.

Nucl Med Biol. 2000 Apr;27(3):233-8.

PMID:
10832079
43.

Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380.

Valette H, Bottlaender M, Dollé F, Guenther I, Fuseau C, Coulon C, Ottaviani M, Crouzel C.

J Nucl Med. 1999 Aug;40(8):1374-80.

44.

Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.

Doll F, Dolci L, Valette H, Hinnen F, Vaufrey F, Guenther I, Fuseau C, Coulon C, Bottlaender M, Crouzel C.

J Med Chem. 1999 Jun 17;42(12):2251-9.

PMID:
10377231
45.

Synthesis of a fluorine-18 labeled derivative of epibatidine for in vivo nicotinic acetylcholine receptor PET imaging.

Dolci L, Dolle F, Valette H, Vaufrey F, Fuseau C, Bottlaender M, Crouzel C.

Bioorg Med Chem. 1999 Mar;7(3):467-79.

PMID:
10220033
46.

Preliminary evaluation of 2-[4-[3-tert-butylamino)-2-hydroxypropoxy]phenyl]-3-methyl-6-me thoxy-4(3H)-quinazolinone ([+/-]HX-CH 44) as a selective beta1-adrenoceptor ligand for PET.

Valette H, Dollé F, Guenther I, Demphel S, Rasetti C, Hinnen F, Fuseau C, Crouzel C.

Nucl Med Biol. 1999 Jan;26(1):105-9.

PMID:
10096509
47.

Characterization of the nicotinic ligand 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine in vivo.

Valette H, Bottlaender M, Dollé F, Guenther I, Coulon C, Hinnen F, Fuseau C, Ottaviani M, Crouzel C.

Life Sci. 1999;64(5):PL93-7.

PMID:
10072197
48.

Synthesis and characterization of a 11C-labelled derivative of S12968: an attempt to image in vivo brain calcium channels.

Dollé F, Valette H, Hinnen F, Fuseau C, Péglion JL, Crouzel C.

Nucl Med Biol. 1998 May;25(4):339-42.

PMID:
9639294
49.

Down-regulation of cardiac muscarinic receptors induced by di-isopropylfluorophosphate.

Valette H, Syrota A, Fuseau C.

J Nucl Med. 1997 Sep;38(9):1430-3.

50.

Synthesis of two optically active calcium channel antagonists labelled with carbon-11 for in vivo cardiac PET imaging.

Dollé F, Hinnen F, Valette H, Fuseau C, Duval R, Péglion JL, Crouzel C.

Bioorg Med Chem. 1997 Apr;5(4):749-64.

PMID:
9158874

Supplemental Content

Loading ...
Support Center